Introduction
The Aurora A (AurA) kinase is overexpressed in a high percent age of tumors arising in breast, colon, ovary, and other tissues (Bischoff et al., 1998; Zhou et al., 1998; Tanaka et al., 1999; Tanner et al., 2000; Goepfert et al., 2002) and functions as an oncogene when exogenously expressed in cell line models for cancer development (Tatsuka et al., 1998; Meraldi et al., 2002; Anand et al., 2003; Zhang et al., 2004) . In normal cells, one im portant function of AurA is as a centrosomally localized regula tor of entry into and passage through mitosis (Marumoto et al., 2005; Pugacheva and Golemis, 2006) ; defects in these roles likely explain the supernumerary centrosomes and aneuploidy that characterize tumor cells with overexpressed AurA. Many studies of AurA performed in mammals and model organisms have shown that AurA kinase activity increases sharply at the G2/M boundary and is highest through M phase in normal cells based on interactions with partner proteins, including TPX2, NEDD9/HEF1, and others (Bayliss et al., 2003; Pugacheva and Golemis, 2005; Hutterer et al., 2006) . Activated AurA detected in interphase cancer cells was initially attributed to a patho logical disease state, unreflective of the role for AurA in normal cells. However, convergence of several lines of investigation has begun to greatly extend known roles for AurA.
Initial evidence for nonmitotic AurA functions arose from a study of the Chlamydomonas reinhardtii aurora protein kinase, a distant orthologue of AurA in the green algae C. reinhardtii (Pan et al., 2004) . This work revealed that C. reinhardtii aurora protein kinase is activated and regulates resorption of the flagella in response to cues for mating or environmental ionic stress, rather than cell cycle cues. Subsequently, our group es tablished that serum growth factors induce AurA activation at the basal body of the cell cilium (a structure analogous to the flagellum) in noncycling G0/G1 mammalian cells causing AurA and NEDD9dependent ciliary resorption (Pugacheva et al., 2007) . We further showed that release of Ca 2+ from the ER to the cytoplasm transiently activated AurA, based on induced direct Ca 2+ calmodulin (CaM) binding to AurA (Plotnikova et al., 2010) . Independently, other groups have found that atypical PKC activates AurA, allowing AurA to phosphorylate NDEL1 and promote microtubule remodeling during neurite extension (Mori et al., 2009 ). AurA has also been found to directly phos phorylate Par6, which together with atypical PKC and Par3 regulates asymmetric cell division and cell polarity (Ogawa et al., 2009; Yamada et al., 2010) . These nonmitotic activities of AurA likely also contribute to deregulation of growth in tumor cells overexpressing AurA. For example, interphaseactive AurA M ost studies of Aurora A (AurA) describe it as a mitotic centrosomal kinase. However, we and others have recently identified AurA functions as diverse as control of ciliary resorption, cell differentiation, and cell polarity control in interphase cells. In these activities, AurA is transiently activated by noncanonical signals, including Ca 2+ -dependent calmodulin binding. These and other observations suggested that AurA might be involved in pathological conditions, such as polycystic kidney disease (PKD) . In this paper, we show that AurA is abundant in normal kidney tissue but is also abnormally expressed and activated in cells lining PKD-associated renal cysts. PKD arises from mutations in the PKD1 or PKD2 genes, encoding polycystins 1 and 2 (PC1 and PC2). AurA binds, phosphorylates, and reduces the activity of PC2, a Ca 2+ -permeable nonselective cation channel and, thus, limits the amplitude of Ca 2+ release from the endoplasmic reticulum. These and other findings suggest AurA may be a relevant new biomarker or target in the therapy of PKD.
Aurora A kinase activity influences calcium signaling in kidney cells or in the loops of Henle. This expression pattern is similar to that previously reported for PC2, which is also abundant in the convoluted tubules and collecting ducts, although PC2 is also abundant in the loops of Henle (Foggensteiner et al., 2000) . AurA staining was generally detectable in the cytoplasm but also intensely concentrated in the nucleus of some cells, with the greatest number of nuclearstaining cells associated with the distal convoluted tubules. Suggestively, a subset of these AurA positive structures also stained positively for T 288 phospho-AurA (phAurA), indicating activity across adjacent groups of non mitotic cells ( Fig. 1 b and Fig. S1 a) ; again, the most intense stain ing was associated with distal convoluted tubules and collecting ducts. As further confirmation, we also examined AurA and phAurA expression in mouse renal tissue (Fig. 1, c and d; and Fig. S1 a) and found a similar expression and activation pattern.
AurA is typically described as solely localized to the centrosome or centrosomally derived ciliary basal body and otherwise hard to detect in noncycling normal mammalian cells. In this context, the fact that cancerous cells with overexpressed AurA have an extensive diffuse pool of cytoplasmic AurA is thought to support the interaction of AurA with substrates with which it does not normally associate (discussed in Pugacheva and Golemis, 2006) . However, we find AurA is intrinsically abundant in HK2 cells, a welldifferentiated cell line derived from the proximal tubules of the human kidney (Ryan et al., 1994) , in primary nontransformed human ovarian surface epi thelial cells (Fig. 2 a) and in noncycling primary mouse kidney cells (Fig. S1 b) . Moreover, siRNA depletion experiments of HK2 cells followed by detection with two different antibodies to AurA (Fig. 2 b and not depicted) indicated the presence of a significant cytoplasmic pool of AurA in interphase HK2 cells in addition to the anticipated concentrated pool of AurA at centrosomes.
We next investigated whether AurA expression, localiza tion, or activation was specifically altered in the context of PKD. Examination of eight primary cysts derived from eight patients with PKD (Fig. 2 c) We have shown that Ca 2+ transiently activates AurA (Plotnikova et al., 2010) , and our data indicate that in the abnormal Ca 2+ sig naling environment associated with PKD renal cysts (Anyatonwu and Ehrlich, 2004) , AurA expression is enhanced. We hypothe sized that AurA might reciprocally influence cellular Ca 2+ levels in a typical signaling feedback circuit (Sneppen et al., 2010) . Indeed, treatment of HK2 and LLCPK1 kidney cells with the AurA inhibitor PHA680632 for 3 h significantly increased basal levels of Ca
2+
, based on measurement of the fluorescence of the cytoplasmic Ca 2+ binding dye Fluo4 (Fig. 3 a; Cai et al., 2004) . Similar results were obtained after depletion of AurA by siRNA in LLCPK1 cells (Fig. 3 b) and HEK293 cells (not depicted).
phosphorylates and promotes the activity of the RalA GTPase, an epidermal growth factor receptor/Ras effector important in many cancers (Wu et al., 2005) . Loss of cilia associated with high level AurA expression would indirectly impact the func tionality of the ciliadependent and cancerrelevant signaling cascades, such as those involving Hedgehog (Wong et al., 2009) .
Pathological conditions of the kidney include renal cell carcinoma, which has been linked to elevated AurA expres sion (Kurahashi et al., 2007) . However, beyond high expres sion in kidney tumors, AurA (Kurahashi et al., 2007) and its partner NEDD9 (Law et al., 1996; Golemis, 2005, 2006) have been predicted to be abundant in normal kidneys. Interestingly, formation of renal cysts is very strongly linked to defects in planar cell polarity control (Fischer et al., 2006; Bacallao and McNeill, 2009) , and the changes in Ca 2+ signaling induced by autosomal dominant polycystic kidney disease (PKD; ADPKD)-associated mutations in the PKD1 and PKD2 genes, encoding the PC1 transmembrane flow re ceptor and the PC2 calcium channel (Hanaoka et al., 2000; Wilson, 2004; Pan et al., 2005; Benzing and Walz, 2006) . Interestingly, an antibody crossreactive with NEDD9 and its paralogue BCAR1/p130Cas has been reported as detecting one of these proteins in a complex with PC1 (Geng et al., 2000) . NEDD9 binds directly to the differentiation regulatory protein Id2 (Law et al., 1999) , which in turn has been reported to bind directly to PC2 and mediate proliferative signals in PKD (Li et al., 2005) . Cumulatively, these studies led us to hypothesize that changes in AurA and/or NEDD9 expression or activity might have a role in signaling processes associated with development of renal cysts.
Based on these and other studies, we have investigated AurA in kidney signaling relevant to cystogenesis. Our work demonstrates that AurA is abundant and frequently active in normal renal tissue and hyperactivated in early renal cysts asso ciated with PKD. We show that low concentrations of drugs that inhibit AurA activity augment basal intracellular Ca 2+ levels in renal cells and PC2dependent Ca 2+ release. We also find that AurA directly binds and phosphorylates PC2, which may pro vide a mechanism by which AurA inhibition limits PC2 Ca 2+ channel activity. ADPKD affects as many as 1 in 500 individ uals and currently has few viable treatment options. The results described here may suggest potential clinical applications of AurA and its inhibitors in better diagnosing or treating this seri ous disease.
Results

Abundant AurA expression and activity in normal kidney tissue and cells and in renal cysts
If AurA has in vivo, noncell cycle function relevant to PKD, AurA should be detectable and potentially active in nondividing renal tissue. Immunohistochemical analysis of primary human kidney specimens readily detected AurA in multiple substruc tures ( Fig. 1 a and Fig. S1 a) . AurA was most concentrated in cells of the proximal and particularly distal convoluted tubules and in the collecting ducts. AurA was not detectable in the glomerulus level (Qian et al., 2003; Geng et al., 2008) . To test whether AurA might modulate intracellular Ca 2+ level through regula tion of the PC2 calcium channel, we used Pkd2 +/ and Pkd2
/ kidney cell lines derived from mutant mice (Grimm et al., 2003; Geng et al., 2008) . Pkd2 / cells have a reduced level of basal
The PC2 Ca 2+ channel is abundant and active in kidney cells. In PKD, PC2 has abnormally reduced function as a result of direct mutation or mutation of its upstream partner PC1 (with which it heterodimerizes at cilia), resulting in abnormal Ca An equivalent response was seen in cells in which histamine was used to induce PC2 channel activity (Fig. S1 , c-e). Recip rocally, treatment of PC2transfected HEK293 cells with the AurA inhibitor PHA680632 (Soncini et al., 2006) signifi cantly enhanced the amplitude of release (Fig. 3, g and h; and Fig. S3 b) . Similar results were obtained using HK2 cells sta bly overexpressing PC2 (Fig. S1 , f-h) and in cells treated with a separate small molecule inhibitor of AurA, C1368 (Fig. S1, i-k) . In PC2overexpressing HK2 cells with AurA depleted by siRNA, AVPinduced Ca 2+ release was significantly increased to a degree comparable with that seen with treatment with AurA inhibitory drugs (Fig. 3, i and j; Fig. S1 l; and Fig. S3 c) . Together, these data strongly implicated AurA as a regulator of PC2 channel activity.
PHA-680632 enhances PC2 activity at low inhibitory concentration (IC) values
Given that one consequence of mutations in PKD1 is to reduce PC2 activation , if AurA inhibition enhances PC2 activity, this might suggest a clinical strategy in PKD arising from mutations in PKD1 (in which the PKD2 gene is structurally Ca 2+ compared with Pkd2 +/ cells as previously described (Fig. 3 c; Geng et al., 2008) . Treatment with the AurA inhibitor PHA 680632 significantly increased intracellular Ca 2+ levels in both Pkd2 +/ and Pkd2 / cells but was less active in Pkd2 / cells ( Fig. 3 c) , whereas the levels of AurA were equivalent in both Pkd2 +/ and Pkd2 / cell lines (Fig. S1 b) . Those data implied that AurA influenced basal Ca 2+ in a process at least partially dependent on intact PC2. We also further demonstrated that PHA680632 did increase basal Ca 2+ level in human kidney cell lines with a mutated PKD1 gene but an intact PKD2 gene (Fig. 3 d ; LoghmanAdham et al., 2003) , as would be expected if the AurA target were downstream of PKD1.
To more directly test whether AurA regulates the PC2 Ca 2+ channel, we transiently transfected HEK293 cells with PC2 together with RFPAurA or an RFP negative control and mea sured fluorescence of the cytoplasmic Ca explanation for the difference in results could be that PHA 680632 was used for only a 2h pretreatment in Ca 2+ release exper iments but must be sustained in culture medium for 3 d in IC 50 determinations: greater compound decay in the latter experiments might stipulate higher initial dosing concentrations. However, in parallel experiments in which PHA680632 was added to media 2 or 24 h before AVP treatment, significantly greater enhancement of PC2 activity occurred with the longer 24h preincubation than the 2h incubation used for other experiments, suggesting drug sta bility was not an issue (Fig. 4, b and c) . These data suggest that AurA may be a useful target in modulating PC2 activity in vivo.
AurA interacts directly with PC2
The bulk (>95%) of intracellular PC2 associates with the ER and mediates Ca 2+ release to the cytoplasm (Cai et al., 1999) . To assess whether there might be direct interactions between AurA, intact). In vivo, Aurora kinase inhibitors have marked effects as cell cycle inhibitors (Gautschi et al., 2008) , which is relevant to their action in cancer therapy, raising the possibility of toxic side effects if these agents were used in PKD. However, a re cent study has suggested that the cytotoxic effects of Aurora kinase inhibitors used in vivo at least partially reflects their cross reactive inhibition of Aurora B rather than AurA, which occurs at higher concentrations (discussed in Gautschi et al., 2008) .
We compared the doses of PHA680632 required to in hibit cell growth with those required to enhance PC2 signals. In HK2 cells, the halfmaximal IC (IC 50 ) value for PHA680632 is 3.25 µM, whereas the 500nM concentration used for the afore mentioned experiments represents an IC 5 value (Fig. 4 a) . In con trast, an approximately twofold enhancement of AVPinduced Ca 2+ release is seen whether PHA680632 is used either at 3.25 µM or at 500 nM (Fig. 4, b and c; and Fig. S3 d) . One possible for positively regulating PC2 Ca 2+ channel activity (Cai et al., 2004) . We identified a strongly consensus candidate AurA phos phorylation motif (Ferrari et al., 2005) at residue S829 (RRGSI), adjacent to the ERtargeting domain, and a less favorable motif at residue S944 (PRSSR). We established that recombinant acti vated AurA phosphorylated the PC2 C terminus in vitro (Fig. 6 b) . AurA phosphorylation of PC2 was enhanced by interactions with NEDD9 (Pugacheva and Golemis, 2005) in contrast to AurA phos phorylation of the control substrate MBP, which was unaffected (Fig. 6 c) . AurA phosphorylation of PC2 was separately enhanced by inclusion of CaM and Ca 2+ in in vitro reactions (Fig. 6 d) . We next compared the ability of AurA to phosphorylate a wildtype PC2 C terminus versus derivatives with S→A mu tations in the S829, S944, or CK2 motifs or combinations of these mutations (Fig. 6, e and f ). An S829A mutation greatly reduced AurA phosphorylation of PC2, resulting in levels close to the background GST negative control, whereas S944A and S812A had no effect on this phosphorylation, either in dependently or in combination with S829A. By comparison, CK2 phosphorylation was reduced to a comparable degree solely by mutation of the S812 residue, whereas CK2 phos phorylation of PC2 was not affected by the presence of S829A or S944A mutations (Fig. 6, g and h) . To investigate the in vivo phosphorylation of the S829 site, we exploited the fact that this site is quite similar to the general PKA substrate con sensus (RRxS). PhosphoPKA substrate antibody recognized PC2, but not S829Amutated PC2, in transiently transfected HEK293 cells (Fig. 6, i and j) . Importantly, cotransfection of constitutively active AurA (T288D) increased phosphoryla tion of this site, whereas treatment of cells with an AurA in hibitor (PHA680632), but not a PKA inhibitor (H89), reduced in vivo phosphorylation. Similar results were obtained using two additional small molecule inhibitors of AurA and after depletion of either AurA or NEDD9 by siRNA (Fig. S2, d and e) . Those data indicate that fulllength PC2 is phosphorylated in vivo at S829. its previously defined partner and activator NEDD9 (Pugacheva and Golemis, 2005) , and PC2, we first established that endog enous AurA and PC2 coimmunoprecipitated from HK2 cells (Fig. 5 a, left) and from primary kidney lysate (Fig. 5 a, middle) . Furthermore, the coimmunoprecipitation was clearly observed in lysates prepared from Pkd2 +/ cells but not in lysates from Pkd2 / cells (Fig. 5 a, right) . We next cotransfected AurA with the GFPtagged PC2 cytoplasmic Cterminal domain (PC2CT, aa 779-968) into HEK293 kidney cells. Overexpressed AurA and PC2CT coimmunoprecipitated (Fig. 5 b and Fig. S2 a) . Furthermore, in a defined in vitro system, recombinant purified fulllength AurA pulled down GSTfused PC2CT (Fig. 5 c and Fig. S2 b) , interacting separately with both the AurA regulatory and catalytic domains (Fig. 5 d) . The PC2 C terminus contains the primary sites for interaction with PC1 (aa 832-895). AurA did not compete with PC1 for binding to PC2 (Fig. 5 e) , sug gesting the utilization of distinct binding sites on PC2.
Finally, in contrast to the results with AurA, although over expressed NEDD9 and PC2 coimmunoprecipitated (Fig. 5 f) , no interaction was seen between endogenous NEDD9 and PC2 or the two purified proteins in vitro system (not depicted). However, the presence of NEDD9 enhances the interaction between AurA and PC2, as siRNA depletion of NEDD9 significantly depleted the degree of coimmunoprecipitation between AurA and PC2CT from HEK293 cells overexpressing these two proteins (Fig. S2 c) . Together, these data suggested a strong and direct interaction be tween AurA and the PC2 C terminus and a significantly weaker or indirect interaction between NEDD9 and PC2 that neverthe less contributed to efficient interactions between AurA and PC2.
AurA phosphorylates PC2 on C-terminal residue S829
Besides the PC1 interaction motif, the PC2 C terminus (Fig. 6 a) encompasses an EF hand, Ca 2+ binding motif (aa 754-782), and ERtargeting sequences (aa 787-820; Giamarchi et al., 2006) . A S812 CK2 (casein kinase 2) phosphorylation site is important with the ER of cells expressing these mutants invariably with an abnormal aggregated morphology within 24 h (Fig. S2 h) and dying within 48-72 h of transfection or transduction. This limi tation made it impossible to reliably assess the consequence of the S829A mutation on PC2 channel activity against a context of dying cells.
Discussion
The work presented here reveals a completely novel activity of AurA in the control of cellular homeostasis for calcium. We have previously shown that transient stimuli, such as AVP or histamine, trigger Ca 2+ release to the cytoplasm, inducing CaM binding and autoactivation of AurA, which is marked by AurA
We have analyzed the consequences of AurA phosphory lation on PC2 expression, localization, and activity. PC2 is known to localize to the ER membrane, ciliary membrane, and plasma membrane. PC2 localized to the ER and to cis portions of the Golgi apparatus are sensitive to endoglycosidase H cleavage, whereas plasma membrane-and cilialocalized forms of PC2 are not (Cai et al., 1999; Koulen et al., 2002) . The AurA inhibi tor PHA680632 did not affect the overall abundance of PC2 or the pool size of endoglycosidase H-cleavable PC2, whether in ciliated or nonciliated HK2 cells (Fig. S2 f) . Subsequent immunofluorescence analysis indicated the degree of localization of the S829A mutant to the ER and cilia is comparable with that of wildtype PC2 (Fig. S2, g and h) . However, the mutation of the AurA phosphorylation site significantly affected ER integrity, AurA binds and phosphorylates PC2 at S 829 , with AurA phos phorylation of PC2 observed both in defined in vitro reactions and in cells. NEDD9 contributes to the specific interaction of S 51 phosphorylation (Plotnikova et al., 2010) . We have now found that AurA negatively regulates the basal Ca 2+ level of renal cells and PC2dependent Ca 2+ release. We have also shown that with mutations affecting a previously defined CK2 site (PC2 S812A ) and two candidate AurA sites (PC2 S829A and PC2 S944A ) alone or in combination were used in in vitro kinase reactions with recombinant AurA. Phosphoimaging of autoradiographs from three independent experiments was quantified (f), and the relative phosphorylation of PC2 779-968 mutants was calculated (graph). Data are expressed as mean values ± SEM of three experiments. *, P < 0.001. (g and h) Experiments as in e and f, except recombinant CK2 was used rather than AurA. *, P < 0.001. (i) Lysates from HEK293 cells overexpressing Myc-tagged PC2 or the Myc-tagged S829A PC2 mutant (Myc) in the presence or absence of AurA or T288D (catalytically active) AurA were used for immunoprecipitation. Cells were treated with 10 µM H89 PKA inhibitor or 500 nM PHA-680632 (PHA) AurA inhibitor for 3 h as indicated. RRxS-directed antibody was used to visualize phosphorylation of the S829 residue (phPC2). Western blot of coimmunoprecipitation from three independent experiments was quantified (j), and relative phosphorylation of PC2 was calculated. Difference versus PC2: *, P < 0.05. WT, wild type.
Id2 all have oncogenic functions. We note that the fact that the activity of AurA inhibitors was reduced, but not completely eliminated, in Pkd2 / cells suggests that PC2 is an important mediator of AurA action in calcium signaling but perhaps not the only relevant AurA target; proteins such as the ryanodine receptor and inositol1,4,5triphosphate receptor are also medi ators of release of calcium from the ER (Anyatonwu and Ehrlich, 2004) and may be influenced by AurA.
Previous studies have identified several regulatory phos phorylation sites on PC2. These include phosphorylation by GSK3 (glycogen synthase kinase 3) at S 76 , CK2 at S 812 , and protein kinase D at S 801 (Cai et al., 2004; Streets et al., 2006 Streets et al., , 2010 . These phosphorylation events affect the localization and Ca 2+ channel activity of PC2, its interaction with partners, such as Id2, and the ability of PC2 to support cell growth (Cai et al., 2004; Köttgen et al., 2005; Li et al., 2005; Streets et al., 2006 Streets et al., , 2010 . The phos phorylation at S 801 within the ERtargeting domain is essential for Ca 2+ release from the ER (Streets et al., 2010) . In contrast, the highly toxic effect of overexpressing the S829A derivative of PC2 in cells, which is accompanied by a "collapsed" morphology to the ER itself, suggests, as one possibility, that this residue may cause gross structural changes in PC2 that damage ER structural integrity while not affecting targeting to the ER.
There is a potential therapeutic benefit to identifying ways to stimulate PC2 channel activity, and there is an urgent need to develop effective therapies for PKD. At present, several targeted therapeutic agents are moving through preclinical development and clinical trials. Besides cSrc, these include agents targeting mammalian target of rapamycin, HER2, and others. These studies provide a precedent for adapting drugs originally developed as cancer therapeutics in PKD. An obvious concern is that, given the chronic but survivable nature of PKD, it is necessary to be ex tremely cautious in using powerful compounds that may them selves ultimately select for oncogenic changes. However, our data suggest that very low doses of an AurAtargeting inhibitor are able to enhance PC2 activity, suggesting a basis for further investigation of such agents in cases of PKD linked to the PKD1 mutation, in which PC2 is insufficiently activated but structur ally intact. It is also fascinating to note that defects in PKD1 and PKD2 have recently been linked to centrosomal amplification in both animal models and human patients (Battini et al., 2008; Burtey et al., 2008) , reducing the separation between cystic syn dromes and cancer and, perhaps, supporting the idea that calcium dependent activation of AurA is relevant to the severity of PKD presentation. Encouragingly, a calcimimetic drug was recently shown to have promise in inhibiting cystic growth in PKD (Gattone et al., 2009 ). There is clearly much room for further investigation.
Materials and methods
Plasmids and constructs Lentiviral constructs were obtained by cloning full-length PKD2 into the pLV-CMV-H4-puro vector (provided by P. Chumakov, Russian Academy of Sciences, Moscow, Russia, and A. Ivanov, West Virginia University, Morgantown, WV). PKD2 cloned in pcDNA3.1-Myc was provided by S. Somlo (Yale University, New Haven, CT). The PKD2-CT fragment (aa 779-968) was cloned into the pEGFP (Takara Bio Inc.) and pGEX-6P1 vectors (Millipore). Amino acid substitution mutations were introduced into wild-type human PKD2 cDNA by site-directed mutagenesis using a AurA with PC2, likely by promoting the ability of AurA to phosphorylate PC2. Inhibition of AurA by small molecule in hibitors enhances PC2 activity, increasing the magnitude of ER Ca 2+ release induced by upstream activators. Our findings that AurA is abundant and frequently active in normal kidney tissue and abnormally expressed in PKDassociated renal cysts to gether provide strong evidence that changes in AurA function may be relevant to the pathogenesis of PKD.
Interestingly, studies of AurA in cancer have often sug gested the prooncogenic activity of AurA may arise because its overexpression allows a normally centrosomal protein access to inappropriate substrates. However, our results suggest changes in AurA expression in cancer may promote quantitative changes in AurA activity more than qualitative phosphorylation of novel substrates. As based on the data presented here, AurA has a broader subcellular localization profile in untransformed kidney cells than is commonly appreciated, with the centrosome acting as a concentration point at which the protein is most readily visualized. This broader view of AurA activity is compatible with recent reports that AurA phosphorylates proteins, such as RalA (Wu et al., 2005) , which are not known for centrosomal lo calization (Clough et al., 2002) . Our data indicate that not only kidney cells but also primary kidney tissue expresses significant quantities of AurA in the cytoplasm and nucleus. They further show that some of this AurA is activated in noncycling cells in normal kidney tissue, particularly in cells of the distal convo luted tubules that collect ducts from which cysts arise. AurA ex pression and activation are further elevated and anomalous in cysts. In this context, it is interesting that two recent studies linked AurA to the function of VHL, one showing direct binding between the two proteins (Ferchichi et al., 2010) , and a second showing that mutation of VHL in renal cell carcinoma induces both AurA and its partner Nedd9/HEF1 (Xu et al., 2010) . Loss of VHL is a major lesion responsible for the development of renal cell carcinoma, which frequently has associated cysts.
In general, calcium signaling differs significantly in can cerous (Roderick and Cook, 2008) and cystic (Harris and Torres, 2009 ) cells versus normal cells, promoting increased cell prolif eration through the abnormal activation of numerous calcium responsive signaling pathways. The fact that AurA activation was elevated in PKDassociated cysts is interesting and may reflect paradoxical activation in the context of mutated PKD1 and PKD2, analogous to the overexpression of growth inhibitory proteins in tumors that have eliminated partners in a feedback loop. The specific mechanism of AurA activation in this patho logical condition bears further investigation. However, based on our results, inappropriately activated AurA may act as an inter mediate in some of signaling processes relevant to PKD. For ex ample, besides binding the PC2 partner Id2, NEDD9 directly binds and is both a target and activator of Src kinase (recently discussed in Singh et al., 2007) . Src signaling is abnormal in PKD, and a recent study has indicated that inhibition of Src produces clinical benefits in PKD (Sweeney et al., 2008) . Through interactions with NEDD9, AurA may influence the ac tivity of Src and Id2 in either normal renal tissue or in cysts. These close physical interactions suggest further topics of study not only in renal cysts but also in cancer, in which NEDD9, Src, and were used either directly for SDS-PAGE or for immunoprecipitation. Immunoprecipitation samples were incubated overnight with an antibody at 4°C and subsequently incubated for 2 h with protein A/G-Sepharose (Thermo Fisher Scientific), washed, and resolved by SDS-PAGE. GST pull-down assays used wild-type AurA (Millipore) mixed with titrated quantities of .
Western blotting was performed using standard procedures and developed by chemoluminescence using the West Pico system (Thermo Fisher Scientific). Primary antibodies included mouse anti-AurA (BD), anti-phAurA-T 288 (Cell Signaling Technology), anti-Myc (Santa Cruz Biotechnology, Inc.), anti--actin mAb (AC15; Sigma-Aldrich), and anti-PC2 (G20 [Santa Cruz Biotechnology, Inc.] and YCC2 [a gift from S. Somlo]). Rabbit anti-GFP (ab290; Abcam) was used for immunoprecipitation, and mouse anti-GFP (JL-8; BD) was used for Western blotting. Anti-GST mAb (Cell Signaling Technology), polyclonal red anti-Flag M2 affinity gel (EZview; SigmaAldrich), and polyclonal anti-AurA agarose immobilized conjugate (IgM; Bethyl) were used for immunoprecipitations. Secondary anti-mouse and anti-rabbit HRP-conjugated antibodies (GE Healthcare) were used at a dilution of 1:10,000 for visualization of Western blots. Image analysis was performed using ImageJ image processing and analysis software (National Institutes of Health) with the signal intensity normalized to -actin or total AurA level.
To assess the AurA phosphorylation of PC2 in vivo, Myc-tagged PC2 was transiently expressed alone or with AurA or T288D-AurA in HEK293 cells and then immunoprecipitated with the anti-Myc antibody. Phosphorylation of the S 829 site was assessed by Western blotting with Phospho-(Ser/Thr) PKA Substrate Antibody (Cell Signaling Technology). 500 nM PHA-680632, 4 µM C1368 (Sigma-Aldrich), or 50 nM MLN8237 (Millennium Pharmaceuticals, Inc.) was used to inhibit AurA, and 10 µM H89 PKA inhibitor (EMD) was used to inhibit phosphorylation. For analysis of PC2 glycosylation, cell lysates were treated with endoglycosidase H (New England Biolabs, Inc.) and analyzed by SDS-PAGE followed by immunoblotting as previously described (Cai et al., 1999; Koulen et al., 2002) .
Kinase assays
To assess phosphorylation of PC2 by AurA, an in vitro kinase assay was performed using bacterially expressed GST-fused PC2-CT and recombinant active AurA or overexpressed AurA immunoprecipitated from mammalian cells in standard kinase buffer with the addition of an Mg/ATP cocktail (Millipore). MBP (Millipore) and histone H1 (Millipore) were used as positive and negative controls for AurA phosphorylation using standard methods. Parallel aliquots without -[
32 P]ATP were processed for SDS-PAGE/Coomassie staining (Invitrogen). To assess CaM-dependent AurA activation, an in vitro kinase assay was performed using AurA purified from baculovirus or according the protocol described in the previous sentence in the presence of 1 µM CaM (EMD) and 1 mM Ca 2+ .
Cytosolic Ca 2+ measurements Cells expressing PC2 constructs were plated on glass coverslips and grown to 80% subconfluence. The coverslips were rinsed in HBSS and incubated with 5 µM Fluo-4 AM in HBSS (Invitrogen) in the presence of 0.02% pluronic acid (Invitrogen) and 2.5 mM probenecid (Invitrogen) for 20-30 min at RT. The coverslips were washed twice in HBSS, mounted in a perfusion chamber (FC2; Bioptechs), and analyzed with a microscope (C1 Spectral confocal) equipped with an NA 1.40 oil immersion 60× Plan Apochromat objective (Nikon) or an NA 1.3 oil immersion 40× Plan Fluo objective (Nikon). Images were acquired using EZ-C1 3.8 software at RT in HBSS media. Cytosolic Ca 2+ measurements performed in the absence of extracellular Ca 2+ were performed on cells washed and assayed in the aforementioned HBSS except that CaCl 2 was omitted and 0.5 M EGTA was added. In experiments involving AurA inhibition, cells were treated for 2-3 h with 500 nM PHA-680632 before calcium measurement. Fluo-4 was excited at 488 nm, and emission was time-lapse recorded at 522 nm. Cells were individually selected, and their fluorescence intensities were normalized to baseline and analyzed with MetaMorph and MetaFluor softwares (Molecular Devices). The area under curve (AUC) was measured using a standard macro in Excel (Microsoft). For basal intracellular calcium measurements, we used the same approach described at the beginning of this paragraph.
To compare cellular responses, we examined differences in intensity over time using a generalized linear model assuming  distribution and log link. We fit the models by generalized estimating of equations assuming an autoregressive correlation structure to account for correlation of observations over time. We included baseline intensity, group, time, and the timegroup interaction in the models. To allow for flexible effects over time, we site-directed mutagenesis kit (QuikChange XL; Agilent Technologies). The Flag-fused C-terminal domain of PKD1 (aa 4,191-4,302) containing the PC1-PC2 interaction site was cloned in the pcDNA3.1(+) vector (Invitrogen). Flag-and GST-fused NEDD9 were expressed from the vectors pCatch-Flag (O'Neill and Golemis, 2001 ) and pGEX-2T (Law et al., 1998) , respectively. AurA and derivatives were expressed from pCMV-SPORT6-C6 (Thermo Fisher Scientific) and pcDNA3.1-monomeric RFP vectors. A PCR product of monomeric RFP1 was ligated into pcDNA3.1(+) (Invitrogen) to create pcDNA3.1-monomeric RFP. pLV-CMV-H4-puro vector, pEFGP, pcDNA3, and HA-BioB (an extensively truncated Escherichia coli BioB expressed from pcDNA3.1-6HA) were used for negative controls (Singh et al., 2008) .
Cell culture and transfection HEK293 cells were maintained in DME with 10% FBS plus penicillin/streptomycin. LLCPK1 (CRL-1392; American Type Culture Collection) cells were maintained in DME/F12 (1:1) with 5% of FBS. The immortalized human kidney proximal tubular cell line (HK-2; catalog no. CRL-219; American Type Culture Collection) was grown to subconfluence in keratinocyte media (Invitrogen). Pkd2
/ and Pkd +/ were provided by S. Somlo and have been previously described (Grimm et al., 2003) . PKD1 mutation-containing WT9-7 (CRL-2830; American Type Culture Collection) and WT9-12 (CRL-2833; American Type Culture Collection) immortalized epithelial cells from ADPKD kidney cysts (Loghman-Adham et al., 2003) were grown in DME with 10% of FBS on flasks coated with 3 mg/ml bovine collagen type I solution. We transiently transfected HEK293 cells with expression constructs for PKDCT, PKD2, NEDD9, and AurA using Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer's instructions. Cells were used for electrophysiological experiments 24-48 h after transfection. For lentiviral infection, pLV constructs were cotransfected with pVSV-G and psPAX2 into the packaging cell line 293-T. After 24 h, media were collected, filtered through a 0.45-µm polyvinylidene fluoride filter (Millipore), and applied to HK-2 cells with 8 µg/µl polybrene (Sigma-Aldrich) for 2 d, with fresh viral supernatant added every 12 h. After 48 h, cells were lysed, analyzed by Western blot analysis, and used for further experiments. HK-2 cells stably expressing PC2 were obtained by infecting the HK-2 cell line with the pLV-PKD2 lentiviral vector and then selecting for 6-10 d with 1 mg/ml puromycin to produce a mass culture as in Pugacheva and Golemis (2005) . PC2 expression was verified by immunoblot and immunofluorescence analyses. Transient transfection of siRNAs was performed using transfection reagent (RNAiMAX; Invitrogen). Cells were assayed after 48 h of transfection. RNA oligonucleotide duplexes targeted to NEDD9 (Hs_NEDD9_2 [SI00657370], 5-CGCTGCCGAAATGAAGTATAA-3, and Hs_NEDD9_1 [SI00657363]) and AurA (Hs_STK6_5 [SI03114111] and Hs_AURKA_1_HP [SI00053452], 5-TCCCAGCGCATTCCTTTGCAA-3) were purchased from QIAGEN as well as scrambled negative controls. After transfection of siRNAs, the degree of depletion of target proteins was determined by Western blotting. IC 50 determinations with the AurA kinase inhibitor PHA-680632 (Nerviano Medical Sciences) were performed as in Skobeleva et al. (2007) .
Immunofluorescence Cells grown on coverslips were fixed with 4% paraformaldehyde for 10 min and then cold methanol for 5 min, permeabilized with 1% Triton X-100 in PBS, blocked in PBS with 3% BSA, and incubated with antibodies using standard protocols. Primary antibodies included mouse anti-AurA (BD), antiacetylated -tubulin mAb (clone 6-11B-1 [Sigma-Aldrich] and clone K(Ac)40 [Enzo Life Sciences]), anti-PC2 (G20 [Santa Cruz Biotechnology, Inc.] and YCC2 [a gift from S. Somlo]), and mouse anti-protein disulfide isomerase mAb (Abcam). Secondary antibodies labeled with Alexa Fluor 488, Alexa Fluor 568, and DAPI to stain DNA were obtained from Invitrogen. Confocal microscopy was performed using a confocal microscope (C1 Spectral; Nikon) equipped with an NA 1.40 oil immersion 60× Plan Apochromat objective (Nikon). Images were acquired at RT using EZ-C1 3.8 (Nikon) software and analyzed using the imaging MetaMorph (Molecular Devices) and Photoshop (version CS2; Adobe) software. Adjustments to brightness and contrast were minimal and were applied to the whole image.
Protein expression, Western blotting, and immunoprecipitation Recombinant GST, GST fused to aa 779-968 of the PC2 C terminus (GST-PC2 779-968 ), and NEDD9 (aa 1-363; previously shown to bind and activate AurA; Pugacheva and Golemis, 2005) were expressed in BL21 (DE3) bacteria, induced with IPTG, and purified using a purification module (MicroSpin GST; GE Healthcare). Purified recombinant AurA was purchased from Millipore. For Western blotting and immunoprecipitation, mammalian cells were disrupted in lysis buffer (CelLytic M; Sigma-Aldrich) supplemented with a protease and phosphate inhibitor cocktails (Roche). Whole-cell lysates entered time and the related interactions in the model using restricted cubic splines assuming 5 knots (Harrell, 2001) . We used Wald tests to assess p-values of group effects at each time point.
Immunohistochemistry
All tissue samples examined were institutional review board-consented, 10-20-mm sections of formalin-fixed, paraffin-embedded tissues, representing either normal human kidney tissue or kidney tissue from patients diagnosed with ADPKD, and archived at the National Disease Resource Interchange. Information about PKD1 versus PKD2 mutational status is unavailable, but based on disease prevalence, the majority of cases likely reflect mutations in PKD1. Samples analyzed were obtained from eight independent patients based on the analysis of a single formalin-fixed, paraffin-embedded tissue specimen for each patient. A standard two-stage indirect immunoperoxidase staining protocol was used for all tissues (Histostain-Plus kit; Invitrogen), with antigen retrieval buffer obtained from BD. As controls, sections were stained with diluent alone (5% goat serum in Tris-buffered saline), and the antibody was preabsorbed with the immunizing peptide. Incubations with tissue sections were performed at RT for 1 h or at 4°C overnight, and subsequent steps were performed at RT. Sections were counterstained with hematoxylin (Sigma-Aldrich). Antibody to total AurA (anti-BTAK antibody; provided by T. Gritsko, University of South Florida, Tampa, FL; with blocking peptide) was used at a dilution of 1:500, and antibody to phospho-T 288 AurA was used at 1:100 (Bethyl). Images were acquired at 10 and 40× using a microscope (Eclipse E600; Nikon).
Statistical analysis
Statistical comparisons were made using a two-tailed Student's t test. Experimental values were reported as the means ± SEM. Differences in mean values were considered significant at P < 0.05. All calculations of statistical significance were made using the InStat software package (GraphPad Software).
Online supplemental material Fig. S1 shows controls for AurA antibody inhibition and siRNA specificity. Fig. S2 analyzes AurA-NEDD9-PC2 interactions, PC2 localization, and expression of PC2 mutants. Fig. S3 shows the analysis of AUC for Fig. 3 (e-j) and Fig. 4 (b and c) . Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.201012061/DC1.
